Progressive Metastatic Castrate Resistant Prostate Cancer Clinical Trials

Progressive Metastatic Castrate Resistant Prostate Cancer

Explore clinical trials studying Progressive Metastatic Castrate Resistant Prostate Cancer. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Progressive Metastatic Castrate Resistant Prostate Cancer trial results

Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056

Conditions: Progressive Metastatic Castrate Resistant Prostate Cancer
Locations: Sarah Cannon Research Institute Denver, Colorado, United States

Sarah Cannon Research Institute Jacksonville, Florida, United States

Emory University Atlanta, Georgia, United States

Wichita Urology Group PA Wichita, Kansas, United States

View all 33 locations

View Trial Details